OPINION:
Americans are facing a drug affordability crisis, and biologic medicines are at the center of it. Despite being just 5% of total prescriptions in the U.S., biologics account for the majority of the nation’s drug spending.
Biosimilars — medications that are structurally and functionally similar to Food and Drug Administration-approved medicines called biologics — are the commonsense, proven solution to the prescription affordability crisis.
The FDA has proved that biosimilars are safe and effective. They treat many illnesses, including chronic skin and bowel diseases such as psoriasis, irritable bowel syndrome, Crohn’s disease and colitis, as well as arthritis, kidney conditions and cancer.
People were interested in these podcasts
Despite the first biosimilar being approved for U.S. use just over a decade ago, the FDA has approved more than 90 biosimilars to date, with more than 70 commercially launched.
Once introduced, biosimilars drive down prices almost immediately. Stelara, a treatment for Crohn’s, psoriasis, colitis and other conditions, is a prime example. Stelara biosimilars were launched at prices up to 90% lower than the brand. A year after the biosimilars launched, the Centers for Medicare & Medicaid Services published its negotiated Maximum Fair Price for Stelara under the Medicare Drug Price Negotiation Program. It was only 66% lower.
Biosimilar competition has proved to lower costs more than CMS negotiations. As more biosimilars enter the market, competition increases choice and low-cost treatment options.
Despite the well-documented benefits of biosimilars, the development pipeline is at risk without a fix to the Inflation Reduction Act’s Biosimilars Special Rule.
Policymakers in Congress must pass the Biosimilars Access and Affordability Act to ensure that biosimilars can compete, reach patients and offer lower costs. With passage of this crucial legislation, this market dynamic can be repeated across dozens of disease states.
Under the Inflation Reduction Act’s Biosimilars Special Rule, Medicare negotiation for a biologic can be delayed for up to two years when there is a “high likelihood” that a biosimilar referencing it will launch at the end of that period.
The law recognized that competition from biosimilars works and lowers costs. It also acknowledged the importance of incentivizing American companies to produce biosimilars, which take years of research and hundreds of millions of dollars in development costs, with an average of 18 years elapsing after a reference biologic’s approval before the first biosimilar reaches patients.
Unfortunately, this “high likelihood” standard has been left open to interpretation, deviating from original congressional intent. It puts lower-cost biosimilars in the crosshairs of Medicare’s subjective decision-making.
A warped interpretation of “high likelihood” affects upstream investment decisions. Companies need certainty that the biosimilars they produce will gain market access and compete with more costly biologics.
The Biosimilars Access and Affordability Act fixes this. The bipartisan legislation would require a biosimilar manufacturer to attest to its upcoming launch and to have a biosimilar on the market by the end of the two-year period. This legislation corrects the implementation of the Biosimilars Special Rule to reflect how biosimilar development and market launches actually occur, and it reinforces a market that works as it should.
The measure requires that reference biologic manufacturers change the behaviors that have previously delayed biosimilar market access. To attest that their biosimilars will launch within the two-year window, developers will need proof that all reference biologic exclusivity and patents have been removed and settled. This requires brand-drug sponsors to actively remove the barriers that prevent biosimilars from coming to market within the two years.
The reference biologic sponsors must compete with biosimilars or negotiate.
• Juliana Reed is executive director of the Biosimilars Forum.

Please read our comment policy before commenting.